Ranbaxy Laboratories announces Q1 results

Ranbaxy Laboratories Ltd has announced the following Unaudited results for the quarter ended March 31, 2008:

The Company has posted a profit after tax of Rs 1034.22 million for the quarter ended March 31, 2008 as compared to Rs 1152.77 million for the quarter ended March 31, 2007. Total Income has increased from Rs 10160.37 million for the quarter ended March 31, 2007 to Rs 10749.66 million for the quarter ended March 31, 2008.

Ranbaxy Laboratories clarifies on news item
With reference to the news item appearing in a leading financial daily titled "Ranbaxy bucks trend o...
Ranbaxy Laboratories - Board Meeting on Feb 19, 2008
Ranbaxy Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company wi...
Ranbaxy Laboratories clarifies on News Item
With reference to news item appearing in leading in financial daily titled "US turns heat on Ranbaxy...
Ranbaxy Laboratories clarifies on news item
Ranbaxy Laboratories Board to consider Audited FY 07 results & to recommend final dividend
Ranbaxy & DBT Collaborate in the area of NDDR - to focus on Tuberculosis Disease segment
Ranbaxy Laboratories - Allotment of equity shares under ESOP
Ranbaxy Laboratories - Outcome of Board Meeting
Ranbaxy Laboratories - “Ranbaxy Receives final US FDA approval to manufacture and market Cetirizine Hydrochlofude Oral Solution”
Ranbaxy Laboratories Board recommends final dividend

Tags: Ranbaxy Laboratories

This entry was posted on Tuesday, April 22nd, 2008 at 9:39 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Hacked by islam_Bey imhatimi.org

Ranbaxy Laboratories announces Q1 results

Leave a Reply